Trademark: 79183501
Word
LONSURF
Status Date
Monday, March 4, 2024
Registration Number
5121586
Registration Date
Tuesday, January 17, 2017
Filing Date
Thursday, October 22, 2015
Published for Opposition
Tuesday, November 1, 2016
5 Pharmaceutical preparations, namely, anti-cancer agents, anti-tumor agents [, anti-ulcerogenic agents, agents for treatment of immunological diseases, agents for the treatment of urinary diseases, agents for pain, antiemetic agents; diagnostic agents, preparations and substances for medical purposes; preparations for detecting genetic predispositions for medical purposes; chemical reagents for medical or veterinary purposes; oiled paper for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; capsules sold empty for pharmaceuticals; eyepatches for medical use; ear bandages; menstruation bandages; sanitary tampons; sanitary napkins; sanitary panties; cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; antiseptic liquid bandages; breast-nursing pads; dental adhesives; dental amalgams; dental cements; dental ceramics; dental polish; dental veneers; material for dental fillings and dental impressions; dental composite materials; dental impression materials; dental restoration compounds; sealing agents for dental purposes; lacteal flour for babies; dietary supplements for humans; dietetic foods, namely, biscuit, jelly, soup adapted for medical use; beverages for babies; food for babies ]
44 Medical diagnostic testing in the fields of cancer, tumors, ulceration, immunological diseases, urinary diseases, nausea, vomiting and pain; providing medical information relating to the treatment or prevention of cancer, tumors, ulceration, immunological diseases, urinary diseases, nausea, vomiting and pain; medical consultation services relating to the treatment and diagnosis of cancer, tumors, ulceration, immunological diseases, urinary diseases, nausea, vomiting and pain; medical counseling services relating to the treatment of cancer, tumors, ulceration, immunological diseases, urinary diseases, nausea, vomiting and pain; genetic testing for medical purposes, namely, for the diagnosis and prognosis of the expected progression of cancer, tumors, ulceration, immunological diseases, urinary diseases, nausea, vomiting and pain; providing medical information relating to the efficacy, side effects, and interactions of pharmaceuticals and medications; medical services; providing medical information; physical examination; [ dentistry; ] preparation and dispensing of medications; medical analysis services for the diagnosis of cancer; medical information services provided via the Internet; providing medical information, consultancy and advisory services; providing information to patients in the field of administering medication; dietetic advisory services; health care services for treating cancer
42 [ Scientific research for medical purposes in the field of cancer, tumors, ulceration, immunological diseases, urinary diseases, nausea, vomiting and pain; testing, inspection, research or evaluation of pharmaceuticals; advisory, consultancy or information services relating to testing, inspection, research or evaluation of pharmaceuticals and medicines; testing, inspection, research or evaluation of medicine, pharmaceutical preparations, and clinical medical trials; advisory, consultancy or information services relating to testing, inspection, research or evaluation of medicine, pharmaceutical preparations, and clinical medical trials; medical and scientific research, namely, conducting clinical trials for medicine; providing medical and scientific research information about the results of clinical trials for pharmaceutical products; design and development of computer hardware and software for use in the field of medicine; research and development of medical technology; providing information about medical and scientific research in the field of pharmaceuticals; scientific research for medical purposes in the area of cancerous diseases; conducting early evaluations in the field of new pharmaceuticals; development of pharmaceutical preparations and medicines; computer programming for the medical sector ]
The mark consists of the wording "LONSURF" in red appearing below two curvy lines, the left one in red and the right curve in red, orange and yellow.
In the statement, line 18,"dietetic beverages adapted for medical purposes" should be deleted. In the statement, lines 25-28, "medical activities or health care" should be deleted, and clinical medical trials should be inserted.
The color(s) red, yellow and orange is/are claimed as a feature of the mark.
Mar 4, 2024
Notice Of Acceptance Of Sec. 71 & 15 - E-Mailed
Mar 4, 2024
Registered - Partial Sec. 71 Accepted & Sec. 15 Ack.
Feb 26, 2024
Case Assigned To Post Registration Paralegal
Feb 9, 2024
Teas Change Of Correspondence Received
Feb 9, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
Feb 9, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 15, 2023
Teas Section 71 & 15 Received
May 26, 2023
Teas Change Of Correspondence Received
May 26, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
May 26, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 17, 2022
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Aug 27, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 27, 2021
Teas Change Of Correspondence Received
Aug 27, 2021
Teas Withdrawal Of Attorney Received-Firm Retains
Aug 27, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Aug 27, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 27, 2021
Teas Change Of Owner Address Received
Nov 1, 2019
Invalidation Reviewed - No Action Required By Office
Oct 11, 2019
Partial Invalidation Of Reg Ext Protection Created
Jan 28, 2019
Correction Under Section 7 - Processed
Jan 24, 2019
Case Assigned To Post Registration Paralegal
Dec 14, 2018
Teas Section 7 Request Received
May 15, 2018
Correction Under Section 7 - Processed
May 13, 2017
Final Decision Transaction Processed By Ib
Apr 21, 2017
Final Disposition Notice Sent To Ib
Apr 21, 2017
Final Disposition Processed
Apr 17, 2017
Final Disposition Notice Created, To Be Sent To Ib
Jan 17, 2017
Registered-Principal Register
Nov 1, 2016
Official Gazette Publication Confirmation E-Mailed
Nov 1, 2016
Published For Opposition
Oct 12, 2016
Notification Of Notice Of Publication E-Mailed
Sep 26, 2016
Electronic Record Review Complete
Sep 23, 2016
On Hold - Electronic Record Review Required
Sep 16, 2016
Approved For Pub - Principal Register
Sep 16, 2016
Examiner's Amendment Entered
Sep 16, 2016
Notification Of Examiners Amendment E-Mailed
Sep 16, 2016
Examiners Amendment E-Mailed
Sep 16, 2016
Examiners Amendment -Written
Aug 31, 2016
Attorney/Dom.Rep.Revoked And/Or Appointed
Aug 31, 2016
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 13, 2016
Refusal Processed By Ib
Mar 18, 2016
Non-Final Action Mailed - Refusal Sent To Ib
Mar 18, 2016
Refusal Processed By Mpu
Mar 18, 2016
Non-Final Action (Ib Refusal) Prepared For Review
Mar 17, 2016
Non-Final Action Written
Mar 4, 2016
Application Filing Receipt Mailed
Feb 29, 2016
Assigned To Examiner
Feb 29, 2016
New Application Office Supplied Data Entered
Feb 26, 2016
Limitation From Original Application Entered
Feb 25, 2016
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
